Mackenzie Financial’s Emergent Biosolutions EBS Stock Holding History

Mackenzie Financial’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,621	Closed	-$231K	–	1453
2021 Q3	$231K	Buy	4,621 +1,004	+28%	+$60.8K	﹤0.01%	1247
2021 Q2	$228K	Buy	+3,617	New	+$232K	﹤0.01%	1137
2019 Q3	–	Sell	-4,820	Closed	-$233K	–	1031
2019 Q2	$233K	Sell	4,820 -900	-16%	-$43.1K	﹤0.01%	1008
2019 Q1	$289K	Buy	+5,720	New	+$337K	﹤0.01%	1114
2018 Q3	–	Sell	-119,689	Closed	-$6.04M	–	1114
2018 Q2	$6.04M	Sell	119,689 -600	-0.5%	-$31.3K	0.02%	411
2018 Q1	$6.33M	Buy	+120,289	New	+$6M	0.02%	397
2016 Q3	–	Sell	-27,342	Closed	-$769K	–	711
2016 Q2	$769K	Buy	+27,342	New	+$1.07M	﹤0.01%	666

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Mackenzie Financial's EBS Position: Q4 2021 in Review

Mackenzie Financial sold out of Emergent Biosolutions (EBS) in Q4 2021, closing a stake of 4,621 shares — an estimated $231K sold.

Mackenzie Financial first reported a position in EBS in Q2 2016 and held it in 7 quarters. The position peaked at $6.33M in Q1 2018. 254 funds tracked by Wall St. Rank hold EBS as of Q4 2021.

Mackenzie Financial reported no remaining Emergent Biosolutions position as of Q4 2021 after selling out during the quarter.
Mackenzie Financial sold 4,621 Emergent Biosolutions shares in Q4 2021, an estimated $231K.
Mackenzie Financial first reported a position in Emergent Biosolutions in Q2 2016 and held it in 7 quarters.
Mackenzie Financial's Emergent Biosolutions position peaked at $6.33M in Q1 2018.
254 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2021.

Based on Mackenzie Financial's 13F filing for Q4 2021, filed 14 Feb 2022.